ヴェルテックス・ファーマシューティカルズは,第2四半期2025年の収益予測を上回り,全年予測を再確認しました. Vertex Pharmaceuticals beat Q2 2025 earnings estimates and reaffirmed full-year guidance.

Vertex Pharmaceuticalsは,調整されたEPSが4.52ドルで,推定値を0.28ドル上回り,年間11.3%増加した2億9400万ドルの収益を報告した. Vertex Pharmaceuticals reported strong Q2 2025 results, with adjusted EPS of $4.52, beating estimates by $0.28, and revenue of $2.94 billion, up 11.3% year-over-year. 会社は2025年度の全収益ガイドを再確認し,EPSで15.63ドルをプロモーションした. The company reaffirmed its full-year 2025 earnings guidance, projecting $15.63 in EPS. 機関による所有は高水準で90.96%であり,UBS Asset Managementは株式を増やし,LRI Investments LLCは保有量を削減した. Institutional ownership remains high at 90.96%, with UBS Asset Management increasing its stake and LRI Investments LLC reducing holdings. 分析官は,株を494.38の目標で"モデレート・バイヤー"とみなす. Analysts rate the stock a "Moderate Buy" with a $494.38 target. 株式は407.79で閉鎖,50日移動平均393.91. The stock closed at $407.79, near its 50-day moving average of $393.91.